19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

Acute Liver Failure (ALF / Fulminant Hepatic Failure)

Acute Liver Failure (ALF), historically designated fulminant hepatic failure, is a rare, devastating syndrome defined by the rapid onset of severe hepatocellular dysfunction with catastrophic systemic consequences.

Clinical Definition & The Diagnostic Triad

To fulfill the diagnostic definition of Acute Liver Failure, a patient must meet three core clinical criteria:

1. Severe Acute Hepatocellular Injury: Manifested by markedly elevated serum aminotransferases (AST and ALT, frequently in the thousands) and jaundice;
2. Absence of Pre-Existing Cirrhosis or Chronic Liver Disease: (Recognized exceptions include acute presentations of autoimmune hepatitis, Wilson disease, and vertically acquired acute hepatitis B virus infection);
3. The Hallmark Coagulopathy & Encephalopathy:
   • Coagulopathy: A prolonged prothrombin time yielding an INR ≥1.5;
   • Hepatic Encephalopathy: Any clinical degree of altered mental status, asterixis, or neuropsychiatric dysfunction developing within 26 weeks of initial symptom onset.

Chronological Classification of ALF

Based on the interval between the onset of jaundice and the appearance of hepatic encephalopathy, ALF is classified into three temporal phenotypes, which carry critical prognostic significance:

• Hyperacute Liver Failure (<7 Days):
  • Typical Etiologies: Acetaminophen overdose, ischemic hepatitis ("shock liver"), hepatitis A virus (HAV), and hepatitis E virus (HEV).
  • Clinical Characteristics: Massive transaminase surges (often >5,000–10,000 IU/L), severe coagulopathy, and early cerebral edema, but moderate jaundice.
  • Prognosis: Carries the highest rate of spontaneous hepatic regeneration and survival with medical management (~60%).
• Acute Liver Failure (7 to 21 Days):
  • Typical Etiologies: Acute hepatitis B virus (HBV) infection.
  • Prognosis: Intermediate spontaneous survival rate (~30–40%).
• Subacute Liver Failure (3 to 26 Weeks):
  • Typical Etiologies: Idiosyncratic drug-induced liver injury (DILI), autoimmune hepatitis, and indeterminate/cryptogenic causes.
  • Clinical Characteristics: Insidious, progressive, severe deep jaundice, mild-to-moderate transaminase elevations, and late encephalopathy.
  • Prognosis: Carries the worst prognosis; spontaneous recovery is <15% to 20%, and emergent liver transplantation is usually required.

---\n

Etiological Spectrum of Acute Liver Failure

                     ETIOLOGICAL SPECTRUM OF ACUTE LIVER FAILURE

  ┌─────────────────────────────────────────┐   ┌─────────────────────────────────────────┐
  │     ACETAMINOPHEN TOXICITY (~50%)       │   │    IDIOSYNCRATIC DILI (~12%)            │
  ├─────────────────────────────────────────┤   ├─────────────────────────────────────────┤
  │ • Leading cause of ALF in US & UK       │   │ • Antimicrobials: INH, Augmentin, Bactrim│
  │ • NAPQI depletes glutathione            │   │ • Antiepileptics: Valproate, Phenytoin  │
  │ • Centrilobular (Zone 3) necrosis       │   │ • Herbal supplements: Green tea, Kava   │
  │ • Specific Antidote: N-ACETYLCYSTEINE   │   │ • Poor spontaneous survival (<20%)      │
  └─────────────────────────────────────────┘   └─────────────────────────────────────────┘
  ┌─────────────────────────────────────────┐   ┌─────────────────────────────────────────┐
  │        VIRAL HEPATITIS (~10%)           │   │      ACUTE WILSON DISEASE (<2%)         │
  ├─────────────────────────────────────────┤   ├─────────────────────────────────────────┤
  │ • HBV (± HDV superinfection / coinfect) │   │ • Coombs-negative hemolytic anemia      │
  │ • HAV in older adults with liver disease│   │ • Alk Phos to Total Bilirubin ratio <4.0│
  │ • HEV: 20-25% mortality in PREGNANCY    │   │ • Kayser-Fleischer rings on slit-lamp   │
  │ • Herpes simplex (HSV) in immunocomp    │   │ • 100% fatal without liver transplant   │
  └─────────────────────────────────────────┘   └─────────────────────────────────────────┘
  ┌───────────────────────────────────────────────────────────────────────────────────────┐
  │                     ISCHEMIC HEPATITIS ("SHOCK LIVER", ~5-10%)                        │
  ├───────────────────────────────────────────────────────────────────────────────────────┤
  │ • Transient severe hypotension, cardiac arrest, cardiogenic shock, or sepsis          │
  │ • Precipitous surge in AST/ALT (>3,000 to >10,000 IU/L) alongside elevated LDH        │
  │ • Rapid >50% transaminase decline within 48 to 72 hours of hemodynamic stabilization  │
  └───────────────────────────────────────────────────────────────────────────────────────┘

1. Acetaminophen (APAP) Hepatotoxicity (~50% of ALF cases in North America):

   • Normal Metabolism: At therapeutic doses (≤4 g/day in adults), 90% of acetaminophen is metabolized in hepatocytes via Phase II glucuronidation and sulfation into nontoxic, water-soluble conjugates excreted in urine. Approximately 5% to 10% is metabolized by cytochrome P450 CYP2E1 into N-acetyl-p-benzoquinone imine (NAPQI), a highly reactive, toxic electrophile. Endogenous hepatic glutathione immediately binds NAPQI, forming nontoxic mercapturic acid and cysteine conjugates.
   • Mechanism of Toxicity: Massive acute ingestion (>7.5 to 10 g in adults, or >150 mg/kg) saturates glucuronidation and sulfation pathways, shifting APAP shunting to CYP2E1. When hepatic glutathione stores fall below 30% of normal baseline, NAPQI can no longer be detoxified. Free NAPQI covalently binds to cysteine sulfhydryl groups on hepatocyte mitochondrial proteins, inducing massive reactive oxygen species generation, opening of the mitochondrial permeability transition pore, loss of ATP synthesis, and extensive centrilobular (Zone 3) hepatic necrosis.
   • High-Risk Vulnerabilities: Chronic alcohol consumption (induces CYP2E1 activity), malnutrition/fasting (depletes baseline glutathione), and concurrent use of CYP-inducing medications (phenytoin, carbamazepine, rifampin) can precipitate catastrophic hepatotoxicity at supratherapeutic doses as low as 4 to 6 g/day.

2. Idiosyncratic Drug-Induced Liver Injury (DILI, ~12% of cases):

   • Non-dose-dependent, unpredictable hepatotoxicity.
   • Common offending agents:
     • Antimicrobials: Isoniazid (INH; black box warning for severe/fatal hepatitis), Amoxicillin-clavulanate (Augmentin; most common cause of cholestatic/mixed DILI), Nitrofurantoin, Trimethoprim-sulfamethoxazole (TMP-SMX);
     • Antiepileptic Drugs: Valproic acid (microvesicular steatosis, hyperammonemic encephalopathy), Phenytoin, Carbamazepine;
     • Herbal and Dietary Supplements: Green tea extract (epigallocatechin gallate), Kava kava, Usnic acid, Black cohosh, anabolic steroids.

3. Viral Hepatitis (~10% of cases):

   • Hepatitis B Virus (HBV): The most frequent viral cause of ALF in North America and worldwide. Acute infection or spontaneous/immunosuppression-induced reactivation of chronic HBV. Coinfection or superinfection with Hepatitis D Virus (HDV) carries a markedly increased risk of fulminant hepatic necrosis.
   • Hepatitis A Virus (HAV): Causes ALF in <0.5% of pediatric cases, but the risk surges to >2% to 3% in adults older than 50 years or those with underlying chronic liver disease.
   • Hepatitis E Virus (HEV): Fecal-oral, waterborne transmission (endemic to South/East Asia and Africa). Carries a catastrophic 20% to 25% mortality rate with fulminant hepatic failure in pregnant females during the second and third trimesters.
   • Herpes Simplex Virus (HSV): Rare but treatable etiology in pregnant women or immunocompromised hosts; presents with high fever, anicteric hepatitis (markedly elevated transaminases with relatively normal bilirubin), and leukopenia; requires immediate high-dose IV acyclovir.

4. Acute Wilson Disease (<2% of cases):

   • Rare, autosomal recessive disorder of biliary copper excretion (ATP7B gene mutation) presenting in children and young adults as hyperacute liver failure.
   • Cardinal Diagnostic Hallmarks:
     1. Severe Coombs-negative microangiopathic hemolytic anemia (caused by massive release of toxic free copper into the bloodstream lysing erythrocyte membranes);
     2. Markedly low Alkaline Phosphatase to Total Bilirubin ratio (<4.0, or <2.0);
     3. Low serum ceruloplasmin and elevated 24-hour urinary copper excretion;
     4. Presence of Kayser-Fleischer rings on slit-lamp ophthalmologic examination (seen in ~50% of acute hepatic presentations);
     5. Untreated acute Wilsonian liver failure carries a 100% mortality rate without emergency liver transplantation.

5. Ischemic Hepatitis ("Shock Liver", ~5–10% of cases):

   • Triggered by transient, profound systemic hypotension, cardiac arrest, cardiogenic shock, or severe sepsis.
   • Biochemical Profile: Characterized by a precipitous, explosive surge in serum AST and ALT (frequently >3,000 to >10,000 IU/L) occurring within 24 hours of the hypotensive insult, accompanied by dramatic elevations in serum lactate dehydrogenase (LDH; AST/LDH ratio typically <1.5).
   • Following hemodynamic stabilization and restoration of cardiac output, transaminases decline rapidly by >50% per day, normalizing within 7 to 10 days.

6. Acute Budd-Chiari Syndrome:

   • Acute thrombotic occlusion of the major hepatic veins or inferior vena cava, frequently associated with underlying myeloproliferative disorders (JAK2 V617F mutation, polycythemia vera) or antiphospholipid syndrome. Presents with painful tender hepatomegaly, rapid-onset intractable ascites, and liver failure; Doppler ultrasound confirms absent hepatic venous flow.

7. Pregnancy-Specific Hepatic Emergencies:

   • Acute Fatty Liver of Pregnancy (AFLP): Occurs in the third trimester (Swansea diagnostic criteria: microvesicular steatosis, hypoglycemia, hyperuricemia, renal dysfunction; linked to fetal homozygous deficiency of long-chain 3-hydroxyacyl-CoA dehydrogenase [LCHAD]). Mandates immediate emergent delivery of the fetus.
   • HELLP Syndrome: Severe preeclampsia variant characterized by Hemolysis, Elevated Liver enzymes, and Low Platelets.

---\n

Acetaminophen Toxicity Protocols & N-Acetylcysteine (NAC)

The Rumack-Matthew Nomogram

               RUMACK-MATTHEW NOMOGRAM FOR ACETAMINOPHEN TOXICITY

  APAP (mcg/mL)
   500 ┼
       │ ● (Peak absorption)
   200 ┼
   150 ┼───────────────────* (Treatment Line: 150 mcg/mL at 4 Hours)
       │                    \
   100 ┼                     \
       │                      \
    50 ┼                       \───────* (Treatment Line: 37.5 mcg/mL at 12 Hours)
       │                                \
       │    NO TOXICITY ZONE             \───────* (4.7 mcg/mL at 24 Hours)
     0 ┴─────┬─────┬─────┬─────┬─────┬─────┬─────┬─────┬─────┬─────┬
             0     4     6     8    10    12    14    16    18    20   24
                              Hours Post-Acute Ingestion

• Strict Scope of Use: Validated exclusively for a single acute ingestion of known timing presenting between 4 and 24 hours post-ingestion.
• Interpretation: Obtain a serum acetaminophen concentration at or after 4 hours post-ingestion. If the plotted level falls on or above the "treatment line" (which starts at 150 mcg/mL at 4 hours and declines logarithmically to 37.5 mcg/mL at 12 hours), antidote therapy is mandatory.
• Nomogram Inapplicability: The nomogram CANNOT be used to evaluate chronic supratherapeutic ingestions, repeated doses over time, ingestions occurring >24 hours prior, or extended-release APAP formulations (which require serial levels 4 to 6 hours apart).

N-Acetylcysteine (NAC): Mechanisms & Clinical Protocols

• Pharmacologic Mechanisms:
  1. Serves as a direct precursor for the synthesis of intracellular glutathione, replenishing depleted hepatic glutathione stores;
  2. Binds and detoxifies free NAPQI directly as a glutathione surrogate;
  3. Provides sulfhydryl groups for sulfate conjugation pathways;
  4. Acts as a potent antioxidant, improves hepatic microcirculatory blood flow, enhances systemic oxygen delivery, and suppresses cerebral edema in established liver failure.
• The Critical 8-Hour Window:
  • When administered within 8 hours of acute ingestion, NAC provides nearly 100% complete protection against severe hepatotoxicity and death.
  • Beyond 8 hours, efficacy progressively declines, but NAC must still be administered at any time point post-ingestion, even days later, as it has been conclusively proven to reduce mortality, cerebral edema, and the need for liver transplantation in established ALF.

[!IMPORTANT] THE EMPIRIC NAC RULE FOR LATE PRESENTATIONS (>8 HOURS): If a patient presents >8 hours after an acute ingestion, or if the time of ingestion is unknown, or if serum transaminases are already elevated, administer the intravenous loading dose of NAC IMMEDIATELY. Do NOT delay antidote administration to wait for laboratory results. If the subsequent 4-hour APAP level falls below the nomogram treatment line and transaminases are normal, NAC can be safely discontinued.

Dosing Protocols for N-Acetylcysteine

• Intravenous 3-Bag Protocol (Total 300 mg/kg over 21 Hours):
  1. Bag 1 (Loading Dose): 150 mg/kg IV in 200 mL 5% Dextrose (D5W) infused over 60 minutes.
  2. Bag 2: 50 mg/kg IV in 500 mL D5W infused over 4 hours.
  3. Bag 3: 100 mg/kg IV in 1,000 mL D5W infused over 16 hours.
  • Continuation Rule: At the conclusion of Bag 3, recheck serum APAP, transaminases, and INR. If APAP is detectable, transaminases remain elevated, or INR >1.5, continue the third-bag infusion rate (6.25 mg/kg/hour or 100 mg/kg over 16 hours) continuously until transaminases are clearly declining and INR is <1.5.
  • Adverse Effects: Anaphylactoid reactions (flushing, urticaria, bronchospasm, angioedema) occur in up to 10% to 15% of IV infusions due to non-IgE-mediated histamine release; managed by temporarily pausing the infusion, administering antihistamines (diphenhydramine), and resuming the infusion at a slower rate.
• Oral 72-Hour Protocol:
  • Loading dose of 140 mg/kg PO, followed by 70 mg/kg PO every 4 hours for 17 additional maintenance doses (total 1,330 mg/kg over 72 hours). Diluted in juice or soda; repeat dose if vomited within 1 hour.

---\n

Critical Care Complications of Acute Liver Failure

1. Cerebral Edema & Intracranial Hypertension (ICH)

Cerebral edema leading to uncal/transtentorial herniation and brainstem death is the leading cause of mortality in hyperacute liver failure.

• Pathophysiology: Severe hepatic dysfunction impairs the urea cycle, causing massive systemic arterial hyperammonemia (>150–200 µmol/L). Circulating ammonia readily crosses the blood-brain barrier into cerebral astrocytes, where glutamine synthetase converts ammonia and glutamate into glutamine. Intracellular accumulation of glutamine exerts a potent osmotic driving force, drawing water into astrocytes, producing cytotoxic astrocyte swelling, cerebral edema, loss of cerebral autoregulation, and intracranial hypertension (intracranial pressure [ICP] >20 mm Hg).
• Critical Management Strategy:
  • Elevate head of bed to 30 degrees; maintain neutral neck alignment to maximize cerebral venous drainage;
  • Elective Endotracheal Intubation: Mandatory for West Haven Grade III or IV encephalopathy to protect the airway and facilitate neuro-monitoring;
  • Target Serum Sodium 145 to 150 mEq/L: Infuse hypertonic 3% sodium chloride to induce mild systemic hypernatremia, creating an osmotic gradient that extracts water from edematous brain parenchyma;
  • Intravenous Mannitol (0.5 to 1.0 g/kg IV bolus): Indicated for acute surges in ICP >20 mm Hg or signs of impending cerebral herniation (sluggish/dilated pupils, decerebrate posturing, Cushing triad);
  • Clinical Pearl: Lactulose and rifaximin, while standard in chronic cirrhotic encephalopathy, have no proven benefit in hyperacute ALF and can cause severe bowel distension that physically impedes emergent liver transplantation.

2. "Rebalanced Hemostasis" & Coagulopathy Management

• The True Physiology: The failing liver loses the capacity to synthesize vitamin K-dependent procoagulant clotting factors (II, VII, IX, X, V), causing marked prolongation of the prothrombin time and elevation of the INR. However, hepatocytes concurrently lose the ability to synthesize endogenous anticoagulant proteins (Protein C, Protein S, and Antithrombin III). Consequently, patients with ALF exist in a fragile state of rebalanced hemostasis and are at equal risk for venous thromboembolism and hemorrhage.
• The Absolute FFP Transfusion Rule:
  • Routine prophylactic transfusion of Fresh Frozen Plasma (FFP) to "correct" an elevated INR in the absence of active bleeding is STRICTLY CONTRAINDICATED.
  • FFP infusion fails to reduce clinical bleeding risks, induces circulatory volume overload, and catastrophically erases the INR—the single most sensitive, dynamic prognostic indicator of hepatic recovery or deterioration.
  • FFP and platelets should be transfused ONLY for active, clinically overt bleeding or immediately prior to high-risk invasive procedures (such as placement of an intracranial pressure monitoring bolt).

3. Metabolic & Infectious Derangements

• Hypoglycemia: Loss of hepatic glycogen stores and impaired gluconeogenesis; requires continuous capillary blood glucose monitoring every 1 to 2 hours and continuous infusion of 10% or 20% dextrose.
• Severe Bacterial & Fungal Sepsis: Impaired reticuloendothelial clearance, complement deficiency, and neutrophil dysfunction; maintain a low threshold for broad-spectrum empiric IV antimicrobials.

---\n

King's College Criteria for Emergent Liver Transplantation in ALF

The King's College Hospital Criteria represent the most widely validated prognostic model worldwide, identifying patients with acute liver failure who have a >80% to 90% predicted in-hospital mortality without emergency orthotopic liver transplantation:

1. Acetaminophen-Induced Acute Liver Failure

Emergency liver transplantation is indicated if the patient meets EITHER of the following criteria:

• Arterial Blood pH <7.30 measured after adequate volume resuscitation (regardless of the grade of encephalopathy);
• OR ALL THREE of the following concurrent criteria (regardless of arterial pH):
  1. Prothrombin time >100 seconds (INR >6.5);
  2. Serum Creatinine >3.4 mg/dL (>300 µmol/L);
  3. West Haven Grade III or IV Hepatic Encephalopathy.

2. Non-Acetaminophen Acute Liver Failure

Emergency liver transplantation is indicated if the patient meets EITHER of the following criteria:

• Prothrombin time >100 seconds (INR >6.5) (regardless of encephalopathy grade);
• OR ANY THREE of the following five unfavorable prognostic factors:
  1. Etiology: Idiosyncratic drug toxicity (DILI) or indeterminate/cryptogenic cause;
  2. Age: <10 years or >40 years;
  3. Duration of Jaundice: Jaundice to encephalopathy interval >7 days;
  4. Prothrombin Time: >50 seconds (INR >3.5);
  5. Serum Total Bilirubin: >17.5 mg/dL (>300 µmol/L).

---\n

Acute Ascending Cholangitis: Pathogenesis, Microbiology & Urgent Decompression

Acute cholangitis is a life-threatening systemic infection of the biliary tree carrying a high mortality if untreated.

Pathophysiology & "Cholo-Venous Reflux"

Development of acute cholangitis requires two concurrent pathophysiologic prerequisites:

1. Mechanical Obstruction of the Biliary Tree: Caused by choledocholithiasis (common bile duct stones; ~70% of cases), benign postoperative or inflammatory biliary strictures, indwelling biliary stent occlusion, or malignant obstruction (pancreatic head adenocarcinoma, cholangiocarcinoma, ampullary cancer);
2. Bacterial Proliferation within Stagnant Bile: Ascending migration of enteric microorganisms from the duodenum through the sphincter of Oddi.

• The Mechanism of Septic Shock: Obstruction causes intrabiliary ductal pressures to rise rapidly above normal physiological limits (>20–25 cm H2O). High hydrostatic pressure breaks down the tight junctions between hepatocytes and biliary canaliculi, precipitating cholo-venous and cholo-lymphatic reflux. Microorganisms and toxic bacterial endotoxins spill directly into the hepatic sinusoids and systemic circulation, triggering overwhelming bacteremia, endotoxemia, and septic shock.

Microbiology of Acute Cholangitis

Infection is typically polymicrobial, reflecting enteric flora:

• Gram-Negative Bacilli: Escherichia coli (most common, isolated in 25–50% of bile and blood cultures), Klebsiella pneumoniae (15–20%), Enterobacter species, Pseudomonas aeruginosa;
• Gram-Positive Cocci: Enterococcus faecalis and Enterococcus faecium (10–20%);
• Anaerobes: Bacteroides fragilis and Clostridium perfringens (especially in elderly patients or those with previous biliary-enteric bypass surgery).

Clinical Diagnostic Criteria: Charcot's Triad & Reynolds' Pentad

                      ACUTE CHOLANGITIS CLINICAL SPECTRUM

  ┌─────────────────────────────────────────────────────────────────────────────────┐
  │ CHARCOT'S TRIAD (Present in 50-70% of cases)                                    │
  │ 1. High Spiking Fever with Rigors (>38.5°C)                                     │
  │ 2. Right Upper Quadrant (RUQ) Abdominal Pain                                    │
  │ 3. Clinical Jaundice (Total Bilirubin >2.0 mg/dL)                               │
  └───────────────────────────────────────┬─────────────────────────────────────────┘
                                          │ Rapid progression if biliary
                                          │ obstruction remains unrelieved
                                          ▼
  ┌─────────────────────────────────────────────────────────────────────────────────┐
  │ REYNOLDS' PENTAD (Indicates Toxic Suppurative Cholangitis; Mortality >50%)      │
  │ • Charcot's Triad (Fever + RUQ Pain + Jaundice)                                 │
  │   PLUS:                                                                         │
  │ 4. Systemic Hypotension / Septic Shock (Systolic BP <90 mm Hg)                  │
  │ 5. Acute Altered Mental Status (Lethargy, Confusion, Delirium)                 │
  │                                                                                 │
  │ EMERGENCY PROTOCOL: Aggressive IV Resuscitation + Broad-Spectrum Antibiotics    │
  │                     + EMERGENT ERCP DECOMPRESSION (<12-24 HOURS)                │
  └─────────────────────────────────────────────────────────────────────────────────┘

Emergency Management of Acute Cholangitis

1. Hemodynamic Resuscitation: Aggressive IV balanced crystalloid infusions to restore intravascular volume; early initiation of norepinephrine if hypotension persists despite fluid loading.
2. Immediate Broad-Spectrum Intravenous Antibiotics: Administer within the first hour of triage after obtaining blood cultures:
   • Piperacillin-tazobactam (Zosyn) 3.375 g to 4.5 g IV every 6 hours; OR
   • Ceftriaxone 1 g to 2 g IV daily PLUS Metronidazole 500 mg IV every 8 hours; OR
   • In patients with severe beta-lactam anaphylaxis or septic shock: Meropenem 1 g IV every 8 hours.
3. Urgent Biliary Decompression:
   • Antibiotics cannot penetrate an obstructed, pressurized biliary system; mechanical decompression is the definitive lifesaving therapy.
   • First-Line Modality: Endoscopic Retrograde Cholangiopancreatography (ERCP) with endoscopic biliary sphincterotomy, stone extraction (balloon or basket), and placement of a biliary drainage stent or nasobiliary catheter.
   • Timing Guidelines (Tokyo Guidelines TG18):
     • Emergent (<12 to 24 Hours): Mandatory for severe cholangitis manifested by Reynolds' pentad, septic shock, organ dysfunction, or failure to clinically improve within 12 hours of IV antibiotics.
     • Early (<24 to 48 Hours): For mild-to-moderate acute cholangitis responding favorably to fluid resuscitation and antibiotics.
   • Alternative Decompression: If ERCP is technically unfeasible (e.g., prior Roux-en-Y gastric bypass) or unavailable, perform Percutaneous Transhepatic Biliary Drainage (PTBD) under fluoroscopic/ultrasound guidance or emergency open surgical T-tube decompression.

---\n

Differential Diagnosis of Severe Jaundice: Pre-Hepatic, Intra-Hepatic & Post-Hepatic

Jaundice (icterus) is the yellow discoloration of the skin, sclerae, and mucous membranes resulting from tissue deposition of bilirubin, clinically detectable when serum total bilirubin exceeds 2.5 to 3.0 mg/dL. Systematic evaluation begins with fractionating serum bilirubin into unconjugated (indirect) and conjugated (direct) components:

Bilirubin Metabolism Essentials

• Senescent red blood cells are phagocytosed by reticuloendothelial macrophages in the spleen and liver, cleaving heme into biliverdin and then unconjugated bilirubin.
• Unconjugated bilirubin is lipid-soluble and water-insoluble; it circulates in plasma tightly bound to albumin. Because it is bound to albumin, unconjugated bilirubin cannot pass the glomerular filtration barrier and NEVER appears in the urine.
• In hepatocytes, uridine diphosphate glucuronosyltransferase (UGT1A1) conjugates bilirubin with glucuronic acid to produce water-soluble conjugated bilirubin.
• Conjugated bilirubin is actively secreted across the canalicular membrane into bile (the rate-limiting step) and enters the small intestine.
• Colonic bacteria deconjugate bilirubin into colorless urobilinogen:
  • ~80% of urobilinogen is oxidized to stercobilin, the brown pigment that colors feces;
  • ~20% of urobilinogen is reabsorbed into the portal circulation; a small portion (~1–2%) is excreted by the kidneys into urine.

Comprehensive Diagnostic Differential Matrix